Circular RNA regulatory role in pathological cardiac remodelling
Research output: Contribution to journal › Review › Research › peer-review
Cardiac remodelling involves structural, cellular and molecular alterations in the heart after injury, resulting in progressive loss of heart function and ultimately leading to heart failure. Circular RNAs (circRNAs) are a recently rediscovered class of non-coding RNAs that play regulatory roles in the pathogenesis of cardiovascular diseases, including heart failure. Thus, a more comprehensive understanding of the role of circRNAs in the processes governing cardiac remodelling may set the ground for the development of circRNA-based diagnostic and therapeutic strategies. In this review, the current knowledge about circRNA origin, conservation, characteristics and function is summarized. Bioinformatics and wet-lab methods used in circRNA research are discussed. The regulatory function of circRNAs in cardiac remodelling mechanisms such as cell death, cardiomyocyte hypertrophy, inflammation, fibrosis and metabolism is highlighted. Finally, key challenges and opportunities in circRNA research are discussed, and orientations for future work to address the pharmacological potential of circRNAs in heart failure are proposed.
| Original language | English |
|---|---|
| Journal | British Journal of Pharmacology |
| ISSN | 0007-1188 |
| DOIs | |
| Publication status | Accepted/In press - 2024 |
Bibliographical note
Funding information: MB is supported by grants from the Slovak Research and Development Agency (APVV-21-0194) and by grants from the Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and the Slovak Academy of Sciences (VEGA 2/0159/24). SG is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—RTG2220—Project Number 281125614. MS and CE are supported by the British Heart Foundation (BHF) Chair Award (CH/15/1/31199) and BHF Programme Grant (RG/20/9/35101) to CE. VS is supported by a fellowship from the Heart Foundation—Daniel Wagner. YD is supported by grants from the Fonds National de la Recherche (FNR) of Luxembourg (C14/BM/8225223, C17/BM/11613033 and COVID-19/2020-1/14719577/miRCOVID), the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 101016072 (A diagnostic test to improve surveillance and care of COVID-19 patients [COVIRNA]), the Ministry of Higher Education and Research of Luxembourg and the Heart Foundation—Daniel Wagner. ST and AH are funded by the HFRI through the ‘1st Call for HFRI Research Projects to support Faculty Members and Researchers, by the Procurement of High-Cost Research Equipment Grant’ (Project Number 2563) and by the ERDF of the EU and Greek National Funds through the EPAnEK call RESEARCH–CREATE–INNOVATE (Project Code Τ2ΕΔΚ-00391). DdG-C has received financial support from the Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041), co-funded by the European Union. CIBERES is an initiative of the Instituto de Salud Carlos III. AYN is supported by the Novo Nordisk Foundation, Denmark (NNF Young Investigator Award 2023) and the Netherlands Organization for Scientific Research (NWO; Women in STEM [2021-18992]). ZZ is funded by the EFSD/Novo Nordisk Foundation Future Leaders Award 2022 (NNF22SA0081227), by the Swedish Research Council (2023-02508), by the Hjärt-Lungfonden (20200326, 20220264 and 20230386) and by the Karolinska Institute KID Grant (202100275 and 202301281). FM is supported by the Italian Ministry of Health (Ricerca Corrente 2024, 1.07.128, RF-2019-12368521 and POS T4 CAL.HUB.RIA, cod. T4-AN-09), by the Italian Cardiology Network IRCCS (RCR-2022-23682288 ), by the Fondazione Telethon (No. 4462 GGP19035A), by the AFM-Telethon (No. 23054) and by the EU-Next Generation EU-NRRP M6C2—Inv.2.1 PNRR-MAD-2022-12375790 and EU PNRR/2022/C9/MCID/I8 FibroThera.
- biomarkers, cardiac remodelling, circular RNAs, heart failure, therapeutic potential
Research areas
ID: 395073762